Skip to main content
Equibles

UBS Group AG

Position in REGN — Regeneron Pharmaceuticals, Inc.

CIK 1610520 ZURICH, V8
Back to REGN Full portfolio

Position in REGN

as of Mar 31, 2026 · filed May 5, 2026
Position Value
$231,775,770
+$22,477,048 QoQ
Shares Held
299,979
+10.6% QoQ
Ownership
0.286%
of shares outstanding
% of Portfolio
0.06%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2020
25 quarters on record
Voting authority Sole 77.89678610836091.ToString("F0")% Shared 0.ToString("F0")% None 22.103213891639083.ToString("F0")%

Common Shares in REGN Over Time

Shares Held

Position Value (USD)

Derivatives in REGN

reported options exposure · as of Mar 31, 2026
CallValue
$7,262,816
CallShares
9,400
PutValue
$9,735,264
PutShares
12,600

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

UBS Group AG holds $8,306,928,575 across 560 Biotechnology names. REGN ranks #8 (2.8% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 ROIV
Roivant Sciences Ltd.
 22,619,472 $626,559,372
2 PTGX
Protagonist Therapeutics, Inc
 5,177,796 $545,739,697
3 ABVX
Abivax S.A.
 4,547,406 $506,353,656
4 RVMD
Revolution Medicines, Inc.
 4,386,791 $426,615,424
5 INSM
INSMED Inc
 1,737,481 $284,112,890
6 VRTX
Vertex Pharmaceuticals Inc / Ma
 630,618 $281,596,158
7 APLS
Apellis Pharmaceuticals, Inc.
 6,206,681 $249,694,775
8 REGN
Regeneron Pharmaceuticals, Inc.
This page 		299,979 $231,775,770

All Filings in REGN

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $7,262,816 9,400
2026-03-31 $9,735,264 12,600
2026-03-31 $231,775,770 299,979
2025-12-31 $209,298,722 271,158
2025-12-31 $11,037,741 14,300
2025-12-31 $9,185,253 11,900
2025-09-30 $190,884,477 339,489
2025-09-30 $12,482,394 22,200
2025-09-30 $9,277,455 16,500
2025-06-30 $154,095,375 293,515
2025-06-30 $11,655,000 22,200
2025-06-30 $11,025,000 21,000
2025-03-31 $19,280,592 30,400
2025-03-31 $37,229,301 58,700
2025-03-31 $182,127,385 287,163
2024-12-31 $52,356,255 73,500
2024-12-31 $86,690,561 121,700
2024-12-31 $272,704,849 382,835
2024-09-30 $75,163,660 71,500
2024-09-30 $285,779,590 271,850
2024-09-30 $108,172,596 102,900
2024-06-30 $267,446,140 254,461
2024-06-30 $102,160,116 97,200
2024-06-30 $72,626,173 69,100
2024-03-31 $78,731,682 81,800
2024-03-31 $112,611,330 117,000
2024-03-31 $247,822,885 257,481
2023-12-31 $118,513,812 134,937
2023-12-31 $121,116,191 137,900
2023-12-31 $96,875,387 110,300
2023-09-30 $85,933,479 104,420
2023-09-30 $103,528,368 125,800
2023-09-30 $87,398,352 106,200
2023-06-30 $115,283,991 160,442
2023-06-30 $55,902,412 77,800
2023-06-30 $74,728,160 104,000
2023-03-31 $83,682,156 101,844
2023-03-31 $61,707,417 75,100
2023-03-31 $98,025,231 119,300
2022-12-31 $115,221,953 159,700
2022-12-31 $89,320,462 123,800
2022-12-31 $100,499,945 139,295
2022-09-30 $35,229,496 51,141
2022-09-30 $109,185,895 158,500
2022-09-30 $83,146,609 120,700
2022-06-30 $73,491,052 124,323
2022-06-30 $95,940,399 162,300
2022-06-30 $67,507,046 114,200
2022-03-31 $73,577,146 105,348
2022-03-31 $72,915,048 104,400

Report a Problem

Category
Description
Email (optional, for follow-up)